<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028560</url>
  </required_header>
  <id_info>
    <org_study_id>2007-280</org_study_id>
    <nct_id>NCT01028560</nct_id>
  </id_info>
  <brief_title>Allergy Immunotherapy for the Reduction of Asthma</brief_title>
  <acronym>AIR</acronym>
  <official_title>Efficacy of Allergy Immunotherapy in Preventing Asthma Morbidity in Atopic, Wheezing Children (Age 18 Months - 3 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jacobi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing
      asthma and allergy related disease in children who had multiple episodes of wheezing and who
      are at high risk for developing persisting asthma. These risks include a history of asthma in
      the parents, allergies to environmental allergens (such as dust mite, cockroach or mouse) and
      other allergic diseases such as eczema or food allergies. Allergy Immunotherapy is not new
      and has been practiced for many years to treat asthma and environmental allergies in older
      children and adults, but has not yet been systematically studied in young children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months)</measure>
    <time_frame>baseline and every two weeks up to end of study (up to 36 months)</time_frame>
    <description>The Asthma Severity Score is a customized score created for this study due to the lack of standardized instruments for this age group. It takes into account asthma symptom severity and frequency, as well as asthma medication dosing and potency. Data was collected at baseline and every 2 weeks through interviews conducted over the phone. If the caregiver could not be reached by the phone, the interview was conducted at the next face-to face opportunity (study or injection visit). The minimum score on this scale is 0 (no asthma symptoms and no asthma medicines used during the 14 day interview period). The maximum score is 224 (uncontrolled severe asthma with severe cough, shortness of breath and wheezing on 14 of 14 days, using Albuterol 2 puffs 4x/day, budesonide/formoterol 160ug/4.5ug 2 puffs twice daily and Montelukast 4mg daily on 14 of 14 days). Scores calculated from the collected data were averaged to produce one reported value at baseline and year 1, 2 and 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Newly Gained Allergic Sensitizations as Assessed by Serum Specific Immunoglobulin E (IgE) Testing</measure>
    <time_frame>Baseline and end of treatment (36 months)</time_frame>
    <description>Young children with allergies tend to develop additional environmental allergies over time. This study investigated if allergy immunotherapy could be used to prevent the development of new allergic sensitizations. Participants were tested for sensitivity to a panel of 8 common environmental allergens. Testing was conducted via serum specific immunoglobulin E (IgE) testing. A test was considered negative (non-allergic) if the specific IgE level was &lt;0.35 kIU/L (Kilo International Units/Liter) and positive (allergic) if the levels was &gt;0.35 kIU/L. A &quot;test pair&quot; is the result of a serum IgE test, for a specific allergen, done at two different times. Test pairs can be negative-negative, negative-positive (newly gained allergic sensitization), positive-negative (lost sensitization) or positive-positive. Reported values indicate the total number of newly gained allergic sensitization (negative-positive) for the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood T Regulatory Cells as a Percentage of CD4+ (Cluster of Differentiation 4) Cells</measure>
    <time_frame>Baseline and every 12 months until end of treatment (36 months)</time_frame>
    <description>T regulatory cells are thought to play a role in mediating the effects of immunotherapy in increasing allergen tolerance and dampen the clinical expression of allergy. However, existing studies have not found clear relationship between numbers of T regulatory cells in blood and effect of immunotherapy. The aim of this analysis was to observe potential changes in T regulatory cell numbers in response to immunotherapy in this age group. Peripheral blood cells were acquired and analyzed for T regulatory (Treg) cell markers. In molecular biology, CD4+ (cluster of differentiation 4), a particular cell marker, is a glycoprotein found on the surface of immune cells such as T helper cells and certain groups of T regulatory cells. Testing was done at baseline and then every 12 months. Reported values represents the percentage of CD4+ that are Treg cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Systemic Corticosteroid Bursts (CSB) Per Child</measure>
    <time_frame>From baseline through end of study (maximum 36 months)</time_frame>
    <description>Any reported use of consequent systemic corticosteroid use due to asthma exacerbation counted as one &quot;corticosteroid burst&quot; (CSB). For example, if a child used 5 days of prednisolone due to asthma exacerbation, this counted as one corticosteroid burst (CSB). An interval of at least 7 days was determined to be necessary to count 2 courses of systemic corticosteroids as separated bursts.
The presented data reflect the intention-to-treat analysis. The time between baseline and each participant's study end time was counted towards the &quot;years in study&quot;. The incidence rate describes the number of CSB per child per &quot;year in study&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Wheezing</condition>
  <condition>Asthma</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>No immunotherapy, receive standard of care asthma treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergen immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergen extracts (subcutaneous injections)</intervention_name>
    <description>Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)</description>
    <arm_group_label>Allergen immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>standard of care asthma and allergy treatment</description>
    <arm_group_label>Allergen immunotherapy</arm_group_label>
    <arm_group_label>No immunotherapy, receive standard of care asthma treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 18 months through 3 years who had at least 2 episodes of wheezing
             prior to enrolment.

          -  Positive skin tests or specific Immunoglobulin E (IgE) antibody titers to at least one
             of common airborne allergens: Dust Mite, cat, cockroach, mouse, dog, pollen (all
             allergy testing can be done at the screening visit at the study site).

          -  The child must also fulfill the criteria for high risk of developing persistent asthma
             by meeting at least one of the following major conditions OR 2 of the following minor
             conditions:

               -  Major criteria: History of atopic dermatitis and/or parental history of asthma.

               -  Minor criteria: MD-diagnosed allergic rhinitis, wheezing unrelated to colds,
                  blood eosinophils above 4%.

        Exclusion Criteria:

          -  The child has a severe systemic condition (other than allergy or asthma) including
             (but not limited to) seizures, major congenital anomalies, physical and intellectual
             delay, cerebral palsy, chest surgery, tuberculosis, primary or secondary
             immunodeficiency or cardiac disorder (except a hemodynamically insignificant atrial or
             ventricular septum defect or heart murmur).

          -  The child was born following 35 or less weeks of gestation.

          -  Parental report that the child received oxygen for more than 5 days in the neonatal
             period, or required mechanical ventilation at any time since birth.

          -  The child fails to thrive, defined as crossing of two major growth percentile lines
             during the last year.

          -  The child has chronic lung disease of prematurity (CLDP), cystic fibrosis or any other
             chronic lung disease.

          -  The child ever received immunotherapy.

          -  The child ever received i.v. gammaglobulins or immunosuppressants (other than
             corticosteroids for asthma).

          -  History of a life-threatening asthma exacerbation which required intubation and
             mechanical ventilation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele de Vos, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Einstein, Jacobi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;(4):CD001186. Review. Update in: Cochrane Database Syst Rev. 2010;(8):CD001186.</citation>
    <PMID>14583928</PMID>
  </reference>
  <reference>
    <citation>Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol. 2006 Feb;117(2):263-8.</citation>
    <PMID>16461125</PMID>
  </reference>
  <reference>
    <citation>Pifferi M, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, Boner AL. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002 Sep;57(9):785-90.</citation>
    <PMID>12169173</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>December 19, 2018</results_first_submitted>
  <results_first_submitted_qc>May 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2019</results_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Gabriele de Vos</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine (Allergy and Immunology)</investigator_title>
  </responsible_party>
  <keyword>Wheezing</keyword>
  <keyword>Asthma</keyword>
  <keyword>Allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>58 children were recruited from one tertiary treatment center, Jacobi Medical Center, which is the largest city hospital in the Bronx, New York. The referral population consists of primarily low-income, Medicaid beneficiaries residing in the Bronx.</recruitment_details>
      <pre_assignment_details>There was no run-in phase. After consents were signed (by the parents), the 58 participants were immediately randomized into treatment or control group. 8 of the 58 participants were withdrawn from the study immediately after randomization, so only 50 participants began protocol treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
          <description>This group consists of children who do not receive allergy immunotherapy. No placebo injections were used. The control group received standard of care asthma and allergy treatment, excluding allergy immunotherapy (subcutaneous or other routes).
Standard of care: standard of care asthma and allergy treatment (medications, advice to environmental remediation)</description>
        </group>
        <group group_id="P2">
          <title>Allergen Immunotherapy</title>
          <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy, this group receives standard of care asthma and allergy treatment (medications, advice to environmental remediation)
Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Standard of care: standard of care asthma and allergy treat</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27">4 of 27 withdrew consent immediately after randomization and are excluded from outcome analysis</participants>
                <participants group_id="P2" count="31">4 of 31 withdrew consent immediately after randomization and are excluded from outcome analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Study Protocol</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Note that of all participants who withdrew from the study, 4 participants in each group (total of 8) withdrew their consent before starting any of the treatment protocol. These 8 withdrawn participants were not included in any analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
          <description>This group only receives standard of care asthma and allergy treatment. This does not receive allergy immunotherapy.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
        </group>
        <group group_id="B2">
          <title>Allergen Immunotherapy</title>
          <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. For safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="0.8"/>
                    <measurement group_id="B2" value="3.0" spread="0.8"/>
                    <measurement group_id="B3" value="3.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic/Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of children with asthma related Emergency Department visits prior to enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months)</title>
        <description>The Asthma Severity Score is a customized score created for this study due to the lack of standardized instruments for this age group. It takes into account asthma symptom severity and frequency, as well as asthma medication dosing and potency. Data was collected at baseline and every 2 weeks through interviews conducted over the phone. If the caregiver could not be reached by the phone, the interview was conducted at the next face-to face opportunity (study or injection visit). The minimum score on this scale is 0 (no asthma symptoms and no asthma medicines used during the 14 day interview period). The maximum score is 224 (uncontrolled severe asthma with severe cough, shortness of breath and wheezing on 14 of 14 days, using Albuterol 2 puffs 4x/day, budesonide/formoterol 160ug/4.5ug 2 puffs twice daily and Montelukast 4mg daily on 14 of 14 days). Scores calculated from the collected data were averaged to produce one reported value at baseline and year 1, 2 and 3.</description>
        <time_frame>baseline and every two weeks up to end of study (up to 36 months)</time_frame>
        <population>All participants were included in this analysis that started immunotherapy, regardless if they completed it or not (intention to treat analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
            <description>This group only receives standard of care asthma and allergy treatment. This does not receive allergy immunotherapy.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
          <group group_id="O2">
            <title>Allergen Immunotherapy</title>
            <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. For safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months)</title>
          <description>The Asthma Severity Score is a customized score created for this study due to the lack of standardized instruments for this age group. It takes into account asthma symptom severity and frequency, as well as asthma medication dosing and potency. Data was collected at baseline and every 2 weeks through interviews conducted over the phone. If the caregiver could not be reached by the phone, the interview was conducted at the next face-to face opportunity (study or injection visit). The minimum score on this scale is 0 (no asthma symptoms and no asthma medicines used during the 14 day interview period). The maximum score is 224 (uncontrolled severe asthma with severe cough, shortness of breath and wheezing on 14 of 14 days, using Albuterol 2 puffs 4x/day, budesonide/formoterol 160ug/4.5ug 2 puffs twice daily and Montelukast 4mg daily on 14 of 14 days). Scores calculated from the collected data were averaged to produce one reported value at baseline and year 1, 2 and 3.</description>
          <population>All participants were included in this analysis that started immunotherapy, regardless if they completed it or not (intention to treat analysis)</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.95" spread="3.74"/>
                    <measurement group_id="O2" value="25.68" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.72" spread="3.52"/>
                    <measurement group_id="O2" value="27.85" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.40" spread="4.16"/>
                    <measurement group_id="O2" value="29.68" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.00" spread="5.23"/>
                    <measurement group_id="O2" value="31.15" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effects model (LME) with random coefficients model was fitted with Restricted Maximum Likelihood estimation. The functional form of the model was quadratic and the model adjusted for gender, race, ethnicity and number of asthma hospitalizations since birth. Unequal data collection were smoothed over two month period with a median score values.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Slope</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>The above is the slope for immunotherapy group . The (quadratic) slope is for 1 month increase in time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effects model (LME) with random coefficients model was fitted with Restricted Maximum Likelihood estimation. The functional form of the model was quadratic and the model adjusted for gender, race, ethnicity and number of asthma hospitalizations since birth. Unequal data collection were smoothed over two month period with median score values.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>The above (quadratic) slope is for control group</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>The above is the (quadratic) slope is for control group and is for 1 month increase in time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effects model (LME) with random coefficients model was fitted with Restricted Maximum Likelihood estimation. The functional form of the model was quadratic and the model adjusted for gender, race, ethnicity and number of asthma hospitalizations since birth. Unequal data collection between immunotherapy and control groups were smoothed over two month period with a median score values.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>Post estimation means were tested between the intervention arms after LME model at year 1 and the p- values were adjusted using Bonferroni correction.</p_value_desc>
            <method>contrast testing post mixed model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.76</ci_lower_limit>
            <ci_upper_limit>12.03</ci_upper_limit>
            <estimate_desc>The difference is IT-Control group and the confidence interval is Bonferroni CI</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effects model (LME) with random coefficients model was fitted with Restricted Maximum Likelihood estimation. The functional form of the model was quadratic and the model adjusted for gender, race, ethnicity and number of asthma hospitalizations since birth. Unequal data collection between immunotherapy and control groups were smoothed over two month period with a median score values.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <p_value_desc>Post estimation means were tested between the intervention arms after LME model at year 2 and the p- value was unadjusted p value</p_value_desc>
            <method>contrast testing post mixed model]</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.83</ci_lower_limit>
            <ci_upper_limit>12.38</ci_upper_limit>
            <estimate_desc>The difference is IT-Control group and the confidence interval is Bonferroni CI</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed effects model (LME) with random coefficients model was fitted with Restricted Maximum Likelihood estimation. The functional form of the model was quadratic and the model adjusted for gender, race, ethnicity and number of asthma hospitalizations since birth. Unequal data collection between immunotherapy and control groups were smoothed over two month period with a median score values.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>Post estimation means were tested between the intervention arms after LME model at year 3 and the p- values were adjusted using Bonferroni correction.</p_value_desc>
            <method>contrast testing post mixed model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.54</ci_lower_limit>
            <ci_upper_limit>15.84</ci_upper_limit>
            <estimate_desc>The difference is IT-Control group and the confidence interval is Bonferroni CI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Newly Gained Allergic Sensitizations as Assessed by Serum Specific Immunoglobulin E (IgE) Testing</title>
        <description>Young children with allergies tend to develop additional environmental allergies over time. This study investigated if allergy immunotherapy could be used to prevent the development of new allergic sensitizations. Participants were tested for sensitivity to a panel of 8 common environmental allergens. Testing was conducted via serum specific immunoglobulin E (IgE) testing. A test was considered negative (non-allergic) if the specific IgE level was &lt;0.35 kIU/L (Kilo International Units/Liter) and positive (allergic) if the levels was &gt;0.35 kIU/L. A &quot;test pair&quot; is the result of a serum IgE test, for a specific allergen, done at two different times. Test pairs can be negative-negative, negative-positive (newly gained allergic sensitization), positive-negative (lost sensitization) or positive-positive. Reported values indicate the total number of newly gained allergic sensitization (negative-positive) for the group.</description>
        <time_frame>Baseline and end of treatment (36 months)</time_frame>
        <population>In the intention to treat analysis, only 30 children (15 in each group) had serum tests available at baseline and after 36 months of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
            <description>This group only receives standard of care asthma and allergy treatment. This does not receive allergy immunotherapy.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
          <group group_id="O2">
            <title>Allergen Immunotherapy</title>
            <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. For safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Newly Gained Allergic Sensitizations as Assessed by Serum Specific Immunoglobulin E (IgE) Testing</title>
          <description>Young children with allergies tend to develop additional environmental allergies over time. This study investigated if allergy immunotherapy could be used to prevent the development of new allergic sensitizations. Participants were tested for sensitivity to a panel of 8 common environmental allergens. Testing was conducted via serum specific immunoglobulin E (IgE) testing. A test was considered negative (non-allergic) if the specific IgE level was &lt;0.35 kIU/L (Kilo International Units/Liter) and positive (allergic) if the levels was &gt;0.35 kIU/L. A &quot;test pair&quot; is the result of a serum IgE test, for a specific allergen, done at two different times. Test pairs can be negative-negative, negative-positive (newly gained allergic sensitization), positive-negative (lost sensitization) or positive-positive. Reported values indicate the total number of newly gained allergic sensitization (negative-positive) for the group.</description>
          <population>In the intention to treat analysis, only 30 children (15 in each group) had serum tests available at baseline and after 36 months of the study.</population>
          <units>Newly gained allergic sensitizations</units>
          <param>Number</param>
          <units_analyzed>test pairs (baseline and at 36+/-6months</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>test pairs (baseline and at 36+/-6months</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.677</p_value>
            <p_value_desc>Chi-square test (proportion of new sensitizations versus unchanged or lost sensitizations in each group, intention-to treat analysis).</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peripheral Blood T Regulatory Cells as a Percentage of CD4+ (Cluster of Differentiation 4) Cells</title>
        <description>T regulatory cells are thought to play a role in mediating the effects of immunotherapy in increasing allergen tolerance and dampen the clinical expression of allergy. However, existing studies have not found clear relationship between numbers of T regulatory cells in blood and effect of immunotherapy. The aim of this analysis was to observe potential changes in T regulatory cell numbers in response to immunotherapy in this age group. Peripheral blood cells were acquired and analyzed for T regulatory (Treg) cell markers. In molecular biology, CD4+ (cluster of differentiation 4), a particular cell marker, is a glycoprotein found on the surface of immune cells such as T helper cells and certain groups of T regulatory cells. Testing was done at baseline and then every 12 months. Reported values represents the percentage of CD4+ that are Treg cells.</description>
        <time_frame>Baseline and every 12 months until end of treatment (36 months)</time_frame>
        <population>Only 27 participants had yearly data for Treg cells from baseline through 36 months (+/- 6 months). Data for 23 participants were not included in the analysis because either parents declined to have blood drawn or because results were not returned from the outside laboratory (despite many efforts to retrieve these data).</population>
        <group_list>
          <group group_id="O1">
            <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
            <description>This group only receives standard of care asthma and allergy treatment. This does not receive allergy immunotherapy.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
          <group group_id="O2">
            <title>Allergen Immunotherapy</title>
            <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment.
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. For safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Blood T Regulatory Cells as a Percentage of CD4+ (Cluster of Differentiation 4) Cells</title>
          <description>T regulatory cells are thought to play a role in mediating the effects of immunotherapy in increasing allergen tolerance and dampen the clinical expression of allergy. However, existing studies have not found clear relationship between numbers of T regulatory cells in blood and effect of immunotherapy. The aim of this analysis was to observe potential changes in T regulatory cell numbers in response to immunotherapy in this age group. Peripheral blood cells were acquired and analyzed for T regulatory (Treg) cell markers. In molecular biology, CD4+ (cluster of differentiation 4), a particular cell marker, is a glycoprotein found on the surface of immune cells such as T helper cells and certain groups of T regulatory cells. Testing was done at baseline and then every 12 months. Reported values represents the percentage of CD4+ that are Treg cells.</description>
          <population>Only 27 participants had yearly data for Treg cells from baseline through 36 months (+/- 6 months). Data for 23 participants were not included in the analysis because either parents declined to have blood drawn or because results were not returned from the outside laboratory (despite many efforts to retrieve these data).</population>
          <units>% of CD4+ cells are Treg cells</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline average Treg %</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.65"/>
                    <measurement group_id="O2" value="5.90" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st Year Treg percentage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="0.66"/>
                    <measurement group_id="O2" value="5.30" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Year Treg percentage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="0.72"/>
                    <measurement group_id="O2" value="5.76" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Year Treg percentage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.499" spread="0.92"/>
                    <measurement group_id="O2" value="7.08" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Covariance Pattern Model with autoregressive covariance structure with REML (Restricted Estimation of Maximum Likelihood) with time and role as categorical variable was modeled.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5460</p_value>
            <p_value_desc>Test of parallelism (group x time) hypothesis P-value.</p_value_desc>
            <method>covariance pattern (rep. measure) model</method>
            <method_desc>Within group difference p-values ( baseline vs 3-years) in control and intervention arm were 0.56 and 0.20 respectively.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
            <estimate_desc>The estimated slope reported is for year 3 from the covariance pattern model with autoregressive covariance structure.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Systemic Corticosteroid Bursts (CSB) Per Child</title>
        <description>Any reported use of consequent systemic corticosteroid use due to asthma exacerbation counted as one &quot;corticosteroid burst&quot; (CSB). For example, if a child used 5 days of prednisolone due to asthma exacerbation, this counted as one corticosteroid burst (CSB). An interval of at least 7 days was determined to be necessary to count 2 courses of systemic corticosteroids as separated bursts.
The presented data reflect the intention-to-treat analysis. The time between baseline and each participant's study end time was counted towards the &quot;years in study&quot;. The incidence rate describes the number of CSB per child per &quot;year in study&quot;.</description>
        <time_frame>From baseline through end of study (maximum 36 months)</time_frame>
        <population>Participants with available data (intention to treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
            <description>This group only receives standard of care asthma and allergy treatment. This does not receive allergy immunotherapy.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
          <group group_id="O2">
            <title>Allergen Immunotherapy</title>
            <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment.
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. For safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Both the experimental group and the control group receive otherwise standard of care asthma and allergy treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Systemic Corticosteroid Bursts (CSB) Per Child</title>
          <description>Any reported use of consequent systemic corticosteroid use due to asthma exacerbation counted as one &quot;corticosteroid burst&quot; (CSB). For example, if a child used 5 days of prednisolone due to asthma exacerbation, this counted as one corticosteroid burst (CSB). An interval of at least 7 days was determined to be necessary to count 2 courses of systemic corticosteroids as separated bursts.
The presented data reflect the intention-to-treat analysis. The time between baseline and each participant's study end time was counted towards the &quot;years in study&quot;. The incidence rate describes the number of CSB per child per &quot;year in study&quot;.</description>
          <population>Participants with available data (intention to treat population)</population>
          <units>Number of CSB per child per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="1.03" upper_limit="1.60"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.26" upper_limit="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis = Incidence rate of CSB in each group are same. Poisson regression adjusting for gender, race and history of hospitalization was used to analyze the corticosteroid burst.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.289</p_value>
            <p_value_desc>Poisson regression model for treatment arm adjusting for gender, race and history of hospitalization was used to analyze the corticosteroid burst and the time period contributed by each child in years were fitted as offset.</p_value_desc>
            <method>Poisson regression</method>
            <method_desc>Poisson regression model with robust variance with contributed person years used as offset was modeled.</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected during the 3-year study period.</time_frame>
      <desc>Definition: Serious adverse events= hospitalization, death
In the immunotherapy group, all allergic or asthmatic events occurring the 48 hours after immunotherapy injections had been administered were considered a possible consequence of immunotherapy (immediate or late allergic reaction). Immediate type reactions were defined as any allergic reaction occurring within 2 hours after the injections.</desc>
      <group_list>
        <group group_id="E1">
          <title>No Immunotherapy, Receive Standard of Care Asthma Treatment</title>
          <description>This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
Standard of care: standard of care asthma and allergy treatment</description>
        </group>
        <group group_id="E2">
          <title>Allergen Immunotherapy</title>
          <description>This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
Allergen extracts (subcutaneous injections): Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-3 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase.
Standard of care: standard of care asthma and allergy treat</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma related hospitalization</sub_title>
                <description>asthma exacerbation requiring hospitalization</description>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis/skin abscess/infected insect bite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic allergic reactions after immunotherapy injections</sub_title>
                <description>Systemic reactions were defined as immediate if occurring within 2 hours after injections and delayed if between 2-48 hours after allergy immunotherapy.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="63" subjects_affected="12" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local allergic reaction after immunotherapy injectionss</sub_title>
                <description>22 of 27 (81%): erythema or induration or edema of  2.5 cm in diameter) 2 of 27 (7%): erythema or induration or edema of &gt; 2.5 cm in diameter but &lt; 50% surface area of upper arm 9 of 27 (33%): mild delayed local reaction</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="128" subjects_affected="22" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabriele de Vos, M.D.</name_or_title>
      <organization>Jacobi Medical Center / Albert Einstein College of Medicine</organization>
      <phone>7184152809</phone>
      <email>gabriele.de-vos@einstein.yu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

